Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Nov 30, 2011	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	1,718	$58.19	926,983
Feb 15, 2024	YANCOPOULOS GEORGE Director, Bd. Co-Chair, President & CSO	Director, Bd. Co-Chair, President & CSO	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	172,723	$399.66	925,209
Nov 30, 2011	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	46,453	$58.19	925,131
Dec 01, 2011	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	3,300	$58.86	923,683
Dec 30, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific	Director, President and Chief Scientific	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	158,079	$52.03	908,303
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	3,430	$8.50	901,079
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	266	$109.29	900,813
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	1,457	$109.29	899,356
Dec 01, 2011	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	24,413	$59.45	899,270
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	55,191	$109.29	897,649

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media